Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15

Authors: Nguyen T. Van,^{1,2,11} Karen Zhang,^{1,2,11} Rachel M. Wigmore,^{1,2} Anne I. Kennedy,^{1,2} Carolina R. DaSilva,^{1,2} Jialing Huang,^{3,12} Manju Ambelil,³ Jose H. Villagomez,^{1,2} Gerald J. O'Connor,^{1,2} Randy S. Longman,⁴ Miao Cao,⁵ Adam E. Snook,^{1,2,5} Michael Platten,^{6,7,8} Gerard Kasenty,⁹ Luis J. Sigal,^{1,2} George C. Prendergast,^{3,10} and Sangwon V. Kim^{1,2,*}

Affiliations:

- ¹ Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
- ² Sidney Kimmel Cancer Center, Jefferson Health, Philadelphia, PA, USA.
- ³ Department of Pathology, Anatomy, & Cell Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA
- ⁴ Jill Roberts Center for IBD, Weill Cornell Medicine, New York, NY, USA.
- ⁵ Department of Pharmacology, Physiology, & Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA
- ⁶ CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
- ⁷ Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany
- ⁸ DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany
- ⁹ Department of Genetics and Development, Irving Medical Center, Columbia University, NY, USA
- ¹⁰ Lankenau Institute of Medical Research, Wynnewood, PA, USA
- ¹¹ These authors contributed equally
- ¹² Present address: Anatomic Pathology, Geisinger Medical Center, Danville, PA, USA

*Corresponding author. Email: svkim@jefferson.edu



Supplementary Fig. 1 AhR is required for GPR15 expression in CD4⁺ T cells, but not in CD8 β^+ or CD4⁻CD8 β^- (DN) T cells. a-b. GPR15 and FOXP3 protein expression in CD4⁺ T cells in the large intestine lamina propria (LILP) at steady state. Wild-type mice (WT: *Ahr*^(fl/fl), n=8) and T cell-specific *Ahr*-deficient mice (*Ahr-CD4*CKO: *CD4^{Cre}Ahr*^(fl/fl), n=7) were used. Representative flow cytometry data, the percentage among CD4⁺ T cells, and the total cell number of each population were shown. Representative of three independent experiments. c. CD8 β^+ T cells and DN T cells in the LILP at a steady state were analyzed for GPR15 expression in the presence (*Ahr*^(fl/fl); n=8) or absence of AhR (*CD4^{Cre}Ahr*^(fl/fl); n=7). Representative of at least three independent experiments. 8-14-week-old mice in C57BL/6 background were used (**a**-c). Data are presented as mean values +/- SEM (**b-c**). Each data point represents the result from one mouse, and p values were calculated by two-sided student's t-test (**b-c**). Source data are provided as a Source Data file (**b-c**).



Supplementary Fig. 2 Dietary supplementation of L-Tryptophan increases GPR15⁺CD4⁺ T cells and their subsequent migration to the LILP.

8-12-week-old *Gpr15^(gfp/gfp)Foxp3^{mrfp}* mice with TJU microbiota in C57BL/6 background were treated with Trp-C or Trp-Sup elementary diets for two weeks, and GPR15 wannabe (GFP⁺) cells and their FOXP3 expression were examined (SILP: small intestine lamina propria; Spln: spleen). The number of mice used: 4 for Trp-C and 5 for Trp-Sup. Data are presented as mean values +/- SEM. Each data point represents the result from one mouse, and p values were calculated by two-sided student's t-test. Source data are provided as a Source Data file.



b



Supplementary Fig. 3 L-Trp supplementation increases GPR15⁺ Tregs in the lymph nodes draining the large intestine and does not induce CCR9 expression.

a-b. GPR15 (in the light blue shade), CCR9 (in the light purple shade), and FOXP3 expression in CD4⁺ T cells in the SILP (**a**) and MLNs-draining the proximal and mid-colon (MLN-L) (**b**). Trp-C (n=10), Trp-Sup (n=10). Combined results of two independent experiments (**a-b**). 8-12-week-old wild-type mice in C57BL/6 background were used (**a-b**). Data are presented as mean values +/- SEM (**a-b**). Each data point represents the result from one mouse, and p values were calculated by two-sided student's t-test(**a-b**). Source data are provided as a Source Data file (**a-b**).



Supplementary Fig. 4 GPR15 expression in CD4⁺ T cells in the large intestine is independent of host enzyme TDO and TPH1.

a. $Tdo2^{(n/+)}$ and $Tdo2^{(n/n)}$ mice were analyzed for GPR15 and FOXP3 expression among CD4⁺ T cells in the LILP at a steady state. Number of mice used: 8 for $Tdo2^{(n/+)}$, and 9 for $Tdo2^{(n/n)}$. **b.** $Tph1^{(+/+)}$, $Tph1^{(n/+)}$, and $Tph1^{(n/n)}$ mice were analyzed for GPR15 and FOXP3 expression among CD4⁺ T cells in the LILP at a steady state. Number of mice used: 4 for $Tph1^{(+/+)}$, 4 for $Tph1^{(n/+)}$ (n=4) and 8 for $Tph1^{(n/n)}$. Combined results of two independent experiments (**a-b**). 8-14-week-old mice in C57BL/6 background were used (**a-b**). Data are presented as mean values +/- SEM (**a-b**). Each data point represents the result from one mouse, and p values were calculated by two-sided student's t-test (**a-b**). Source data are provided as a Source Data file (**a-b**).



Supplementary Fig. 5 Seven selected chemical compounds induce *Gpr15*-GFP expression through AhR. CD4⁺ naïve T cells (CD62L^{hi}CD44^{lo}mRFP⁻CD25⁻GFP⁻CD4⁺) from 8-14-week-old wild-type (*Ahr*^(fl/fl)*Gpr15*^(gfp/+)*Foxp3^{mrfp}*), or *Ahr* KO (*Ahr*^{(n/n}*Gpr15*^(gfp/+)*Foxp3^{mrfp}*), or *Ahr*-*CD4*CKO (*Cd4^{Cre}Ahr*^(fl/fl)*Gpr15*^(gfp/+)*Foxp3^{mrfp}*) mice in C57BL/6 background were stimulated with anti-CD3ε and anti-CD28 antibody for 2-3 days with or without hTGFβ1 (0-3 ng/ml) and the selected chemical compounds in Fig. 4A. The following concentration ranges of the compounds were used: I3-PYA (100-300 µM), I3-S (1-3 µM), Pyocyanin (300 nM-1 µM), FICZ (3-6 µM), ANI-7 (100-300 nM), BaP (100 nM-1 µM), b-NF (300 nM-1 µM). GFP signals dependent on AHR are labeled in the histograms (dark peaks: WT; gray peaks: KO or CKO).



Supplementary Fig. 6 GPR15 expression in $CD8\beta^+$ T cells and DN T cells in the LILP is affected by the binding of the transcriptional factors, other than AhR.

8-12-week-old $Gpr15^{(gfp/w)}$ (n=6), $Gpr15^{(gfp/TF\Delta)}$ (n=7), and $Gpr15^{(gfp/DREmut1)}$ (n=6) mice in C57BL/6 background. Cell numbers and population percentages are shown. Representative of two independent experiments. Data are presented as mean values +/- SEM. Each data point represents the result from one mouse, and p values were calculated by two-sided student's t-test. Source data are provided as a Source Data file.



Supplementary Fig. 7 The decrease of $IFN\gamma^+$ cells and $IFN\gamma^+IL-17A^+$ accompanies dietary L-Trp-mediated increase of GPR15⁺ Tregs in the large intestine.

a-c. Murine CD4⁺ T cells from LILP were stimulated in the presence of GolgiStop, PMA, and Ionomycin for 3 hr and stained intracellularly for cytokines. **a.** 8-12-week-old wild-type C57BL/6 mice (n=10) at steady state with Taconic microbiota were used. The percentages of GPR15⁺ and GPR15⁻ cells among cytokine-producing cells were shown. Representative of two independent experiments. **b.** 8-14-week-old mice in C57BL/6 background with TJU microbiota 1 (SFB-free, Fig. 3b) were fed three different types of elementary diets *ad libitum* for three weeks as shown in Fig. 1c-d. Cells from WT (*Ahr*^(*Il*/*I*)*Gpr15*^(gfp/+)*Foxp3*^{mr/p}) and *Ahr-CD4*CKO mice (*Cd4*^{Cre}*Ahr*^(*Il*/*I*)*Gpr15*^(gfp/+)*Foxp3*^{mr/p}) were compared. Number of mice used: WT with Trp-C (n=8), Trp-Sup (n=7), or Trp-Def (n=3), *Ahr-CD4*CKO with Trp-C (n=8), Trp-Sup (n=14), or Trp-Def (n=4). Combined results of three independent experiments. **c.** 8-12-week-old wild-type C57BL/6 mice with Taconic microbiota were fed with Trp-C (n=10) or Trp-Sup (n=9) for 2 weeks and analyzed. Representative of two independent experiments. Data are presented as mean values +/- SEM (**a-c**). Each data point represents the result from one mouse, and p values were calculated by two-sided student's t-test (**a-c**). Source data are provided as a Source Data file (**a-c**).



Supplementary Fig. 8 L-Trp supplementation after colitis onset does not reduce the

severity of colitis. a. Experimental plan for the treatment of colitis. **b.** Pathology scores of the large intestine of 8-12-week-old wild-type C57BL/6 mice. Representative of two independent experiments. Number of mice used: WT with Control diet (n=10), WT with Trp-Sup (n=10). Data are presented as mean values +/- SEM. Each data point represents the result from one mouse. Source data are provided as a Source Data file (**b**).



Supplementary Fig. 9 Gating strategy for CD4⁺ T cells. DAPI or Fixable blue were used to exclude dead cells from the analysis.

Supplementary Table 1. Composition of each elementary diet.

The total nitrogen intake of mice remained the same across different diets by adjusting the amount of non-essential amino acids.

| Formula (g/kg) | Trp-C (TD.07788) | Trp-Sup (TD, 170745) | Trp-Def (TD, 08467) | Trp-Lo (TD, 200535) | | | |
|---|---------------------|-------------------------|------------------------|------------------------|--|--|--|
| L-Alanine | 3.5 | 3.5 | 3.5 | 3.5 | | | |
| L-Arginine HCI | 12.1 | 12.1 | 12.1 | 12.1 | | | |
| L-Asparagine | 6.0 | 6.0 | 6.0 | 6.0 | | | |
| L-Aspartic Acid | 3.5 | 3.5 | 3.5 | 3.5 | | | |
| L-Cystine | 3.5 | 3.5 | 3.5 | 3.5 | | | |
| L-Glutamic Acid | 40.0 | 24.5 | 41.8 | 42.33 | | | |
| Glycine | 23.3 | 23.3 | 23.3 | 23.3 | | | |
| L-Histidine HCI, monohydrate | 4.5 | 4.5 | 4.5 | 4.5 | | | |
| L-Isoleucine | 8.2 | 8.2 | 8.2 | 8.2 | | | |
| L-Leucine | 11.1 | 11.1 | 11.1 | 11.1 | | | |
| L-Lysine HCI | 18.0 | 18.0 | 18.0 | 18.0 | | | |
| L-Methionine | 8.6 | 8.6 | 8.6 | 8.6 | | | |
| L-Phenylalanine | 7.5 | 7.5 | 7.5 | 7.5 | | | |
| L-Proline | 3.5 | 3.5 | 3.5 | 3.5 | | | |
| L-Serine | 3.5 | 3.5 | 3.5 | 3.5 | | | |
| L-Threonine | 8.2 | 8.2 | 8.2 | 8.2 | | | |
| L-Tryptophan | 1.8 | 12.5 | 0 | 0.2 | | | |
| L-Tyrosine | 5.0 | 5.0 | 5.0 | 5.0 | | | |
| L-Valine | 8.2 | 8.2 | 8.2 | 8.2 | | | |
| Sucrose | 344.53 | 349.23 | 344.43 | 343.72 | | | |
| Corn Starch | 150.0 | 150.0 | 150.0 | 150.0 | | | |
| Maltodextrin | 150.0 | 150.0 | 150.0 | 150.0 | | | |
| Soybean Oil | 80.0 | 80.0 | 80.0 | 80.0 | | | |
| Cellulose | 30.0 | 30.0 | 30.0 | 30.0 | | | |
| Mineral Mix, AIN-93M-MX | 35.0 | 35.0 | | | | | |
| (94049) | | | 35.0 | 35.0 | | | |
| Calcium Phosphate, | 8.2 | 8.2 | | | | | |
| monobasic, monohydrate | | | 8.2 | 8.2 | | | |
| Vitamin Mix, AIN-93-VX | 19.5 | 19.5 | 19.5 | 19.5 | | | |
| (94047) | | | | | | | |
| Choline Bitartrate | 2.75 | 2.75 | 2.75 | 2.75 | | | |
| | 0.02 | 0.02 | | | | | |
| TBHQ, antioxidant | | | 0.02 | 0.02 | | | |
| Food color | | 0.1 | 0.1 | 0.1 | | | |
| Selected Nutrient Information (% by weight) | | | | | | | |
| Protein | 15.4 | 15.4 | 15.3 | 15.4 | | | |
| | 64.8 | 65.3 | 64.8 | 64.8 | | | |
| ⊢at | 8 | 8 | 8 | 8 | | | |

| SOURCE | CHEMICAL NAMES | ABBREV | CAS# | RANGE OF CONCENTRATI |
|-------------------|---|----------------------------|-------------|-------------------------|
| | | IATION | | ON TESTED |
| | 1-Hydroxyphanazine | 1-HP | 528-71-2 | 1 nM-10 μM |
| | 1,4 -Dihydroxy- 2 -naphthoic acid | 1,4-DH-2- NA | 31519-22-9 | 1 nM-1 μM |
| | 2,8-Quinolinediol | | 15450-76-7 | 1 nM-100 μM |
| | 3 -Methylindole | 3M-indole | 83-34-1 | 1 nM-100 μM |
| | Indole-3-acetaldehyde | I3-acetAld | 20095-27-6 | 1 nM-10 µM |
| | Indole- 3 -acrylic acid | I3-acrylA | 1204-06-4 | 1 nM-100 μM |
| Microbe- | Indole-3-carboxaldehyde | I3-caAld | 487-89-8 | 1 nM-100 μM |
| derived | 3 -Indolelactic acid | I3-LA | 832-97-3 | 1 nM-1 mM |
| | Indole- 3 -propionic acid | I3-PA | 830-96-6 | 1 nM-1 mM |
| | Indole- 3 -pyruvic acid | I3-PYA | 392-12-1 | 1 nM-100 μM |
| | Indirubin | | 906748-38-7 | 1 nM-10 µM |
| | Indole | | 120-72-9 | 1 nM-100 µM |
| | Indoxyl sulfate | I3-S | 2642-37-7 | 1 nM-100 µM |
| | Pyocyanin | | 85-66-5 | 1 nM-1 µM |
| | 3,3 '-diindolylmethane | | 1968-05-4 | 1 nM-10 µM |
| | Astaxanthin | | 472-61-7 | 1 nM-10 µM |
| | Benzothiazole | | 95-16-9 | 1 nM-100 µM |
| | Biochanin A | | 491-80-5 | 1 nM-10 µM |
| | Curcumin | | 458-37-7 | 1 nM-1 µM |
| Plant- derived | Diosmin | | 520-27-4 | 1 nM-100 μM |
| | Indole- 3 -acetic acid | I3-acetA | 6505-45-9 | 1 nM-100 µM |
| | Indole-3-acetamide | I3-AM | 879-37-8 | 1 nM-100 µM |
| | Indole-3-acetonitrile | I3-ACN | 771-51-7 | 1 nM-100 µM |
| | Indole-3-carbinol | I3-CBL | 700-06-1 | 1 nM-100 μM |
| | Indigo | | 482-89-3 | 1 nM-100 μM |
| | Myricetin | | 529-44-2 | 1 nM-100 μM |
| | Norisoboldine | | 23599-69-1 | 1 nM-10 µM |
| | Resveratrol | | 501-36-0 | 1 nM-10 µM |
| | Tryptamine | | 61-54-1 | 1 nM-10 µM |
| Host- derived | 3 -Hydroxyanthranilic acid | 3H- anthranilic acid | 548-93-6 | 1 nM-10 μM |
| | 3 -Hydroxy-DL-kynurenine | 3H-Kyn | 484-78-6 | 1 nM-100 μM |
| | 5-hydroxy Indole-3-acetic Acid | 5-HIAA | 54-16-0 | 10 nM-100 μM |
| | 5-Hydroxy-L-Tryptophan | 5-HTP | 4350-09-8 | 10 nM-100 μM |
| | 5S,6R-dihydroxy- | 5(S),6(R)- DiHETE | 82948-88-7 | 1 mM 100 mM |
| | eicosatetraenoic acid | | | 1 μνι-100 μινι |
| | Anthranilic acid | | 118-92-3 | 1 nM-100 μM |
| | Bilirubin | | 635-65-4 | 1 nM-10 μM |

Supplementary Table 2. Chemical compounds used for in vitro screening in Fig. 4a

| | Biliverdin | | | 1 nM-100 μM |
|-------------------|--|----------|-------------|-----------------|
| | Cinnabarinic acid | | 606-59-7 | 1 nM-100 µM |
| | 6-Fomylindolo(3,2-b)carbazole | FICZ | 172922-91-7 | |
| | 2-(1H-Indol-3-ylcarbonyl)-4- | | | |
| | thiazolecarboxylic acid methyl | ITE | 448906-42-1 | 1 nM-100 μM |
| | ester | | | |
| | Kynurenic acid | | 492-27-3 | 1 nM-100 μM |
| | L-Kynurenine | | 2922-83-0 | 1 nM-100 μM |
| | Melatonin | | | 10 nM-100 µM |
| | Picolinic acid | | | |
| | Prostaglandin G2 | | 51982-36-6 | 1 nM-10 μM |
| | Quinolinic acid | | 89-00-9 | 1 nM-100 μM |
| | Serotonin | | | 1 nM-100 µM |
| | Xanthurenic acid | | 59-00-7 | 1 nM-100 µM |
| | 1,2-Naphthoquinone | | 524-42-5 | 1 nM-1 µM |
| | 1,4-Naphthoquinone | | 130-15-4 | 1 nM-1 µM |
| | 10-chloro-7H-benzimidazo[2,1- | 10-CL- | 22082 76 5 | 1 nM-10 nM |
| Anthropoge nic | a]benzo[de]isoquinolin-7-one | BBQ | 23982-76-5 | |
| | 7,12- | 7,12- | 57-97-6 | 1 nM-10 μM |
| | Dimethylbenz[a]anthracene | DMBA | | |
| | Alpha-naphthoflavone | Alpha-NF | 604-59-1 | 1 nM-10 μM |
| | (Z)-2-(3,4-dichlorophenyl)-3- | ANI-7 | 931417-26-4 | 1 nM-10 µM |
| | (1H-pyrrol-2-yl)acrylonitrile | | | |
| | Benzo[a]pyrene | BaP | 50-32-8 | 1 nM-10 μM |
| | Beta-napthoflavone | Beta-NF | 6051-87-2 | 1 nM-100 μM |
| | Leuflunomide | | 75706-12-6 | 1 nM-10 μM |
| | Mesalamine | | 89-57-6 | 1 nM-100 μM |
| | 1-allyl-3-(3,4- | | | |
| | dimethoxyphenyl)-7- | SGA360 | 680611-86-3 | 1 nM-10 μM |
| | (trifluoromethyl)-1H-indazole | | | |
| | 7-Oxo-7 <i>H</i> -benzimidazo[2,1- | | | 1 nM-10 μM |
| | <i>a</i>]benz[de]isoquinoline- 3 - | STO-609 | | |
| | carboxylic acid | | | |
| | 2,3,7,8-tetrachlorodibenzo- <i>p</i> - | TCDD | 1746-01-6 | 1 nM-100 nM |
| | dioxin | 1000 | | 1 1111 100 1111 |
| | 6,2,4-Trimethoxyflavone | TMF | 720675-90-1 | 1 nM-10 µM |